Top of this page
Skip navigation, go straight to the content
Scroll down to discover UCB
Rozanolixizumab (UCB7665)
| Disease area studied |
Abbreviated title | Phase | Study ID | Registry database | Study results | Lay summary | Publication (if available) |
|---|---|---|---|---|---|---|---|
| Chronic Inflammatory Demyelinating Polyradiculoneuropathy | A Study to Assess the Efficacy, Safety and Tolerability of Rozanolixizumab in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy |
CIDP01 Recruitment On Hold |
|||||
| Chronic Inflammatory Demyelinating Polyradiculoneuropathy | A Study to Assess Long-term Safety, Tolerability and Efficacy of Rozanolixizumab in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy |
CIDP04 Ongoing |
|||||
| Myasthenia Gravis | A Multicenter, Randomized, Investigator- and Subject-Blind, Placebo-Controlled, Treatment Sequence Study Evaluating the Safety, Tolerability, and Efficacy of UCB7665 in Subjects With Moderate to Severe Myasthenia Gravis |
MG0002 Completed |
NCT03052751 2016-002698-36 |
Bril V., Neurology 2019; 92(15 suppl.), abs S43.001 | |||
| Myasthenia Gravis | A Study to Test Efficacy and Safety of Rozanolixizumab in Adult Patients With Generalized Myasthenia Gravis |
MG0003 Recruitment On Hold |
|||||
| Myasthenia Gravis | A Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Rozanolixizumab in Adult Patients With Generalized Myasthenia Gravis |
MG0004 Ongoing |
NCT04124965 | ||||
| Thrombocytopenia | Study to Evaluate Safety, Tolerability and Efficacy of UCB7665 in Subjects With Primary Immune Thrombocytopenia |
TP0001 Completed |
NCT02718716 2015-003984-12 |
LINK |
Robak, T.; Kaźmierczak, M.; Jarque, I.; Musteata, V.; Treliński, J.; Cooper, N. et al. (2019): Blood 134 (suppl.1) abs 897. ASH 2019 | ||
| Primary Immune Thrombocytopenia | The Purpose of This Study is to Demonstrate the Clinical Efficacy of Rozanolixizumab in Maintenance Treatment and Asses Safety and Tolerability of Rozanolixizumab in Adult Study Participants with Primary Immune Thrombocytopenia (ITP). |
TP0003 Recruitment On Hold |